Sheep Anti-Anthrax Protective Antigen IgG ELISA Kit

Sample

Serum or Plasma

Species Reactivity

Sheep

Detection Method

iELISA

Intended Use

The Sheep Anti-Anthrax Protective Antigen (PA83) IgG ELISA Kit is an immunoassay suitable for quantifying or titering IgG antibody activity specific for PA83 in serum or plasma of sheep, Other biological fluids, including tissue culture medium, may be validated for use.

Contents of Kit

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label. Stabilities of the working solutions are indicated under Reagent Preparation.

Sensitivity

The PA83 coating level and HRP conjugate concentration are optimized to differentiate anti-PA83 IgG from background (nonantibody) signal with sheep serum samples diluted 1:200.

General Description

Anthrax, a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis, has become a biological warfare agent of concern due to the stability and extreme lethal consequences of human inhalation of spores. Exposure to infected animals or tissue is also a major safety concern. The disease can occur in three forms: cutaneous, gastrointestinal and inhalation. Spores can remain viable and infective in the soil for many years.
B. anthracis evades the immune system by producing an antiphagocytic capsule. In addition, three proteins - protective antigen (PA), lethal factor (LF), and edema factor (EF) – are produced that act in combinations to form two exotoxins known as lethal toxin and edema toxin. Development of improved vaccines for protection of livestock and for human immunization have involved preparations that include combinations of these antigens.
Immunoassays that measure titer of host antibody directed against the specific B. anthracis antigens can be used to study the efficacy of experimental anthrax vaccines and the exposure to the bacterium and/or separate antigens.

General Notes

Anthrax, a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis, has become a biological warfare agent of concern due to the stability and extreme lethal consequences of human inhalation of spores. Exposure to infected animals or tissue is also a major safety concern. The disease can occur in three forms: cutaneous, gastrointestinal and inhalation. Spores can remain viable and infective in the soil for many years.
B. anthracis evades the immune system by producing an antiphagocytic capsule. In addition, three proteins - protective antigen (PA), lethal factor (LF), and edema factor (EF) – are produced that act in combinations to form two exotoxins known as lethal toxin and edema toxin. Development of improved vaccines for protection of livestock and for human immunization have involved preparations that include combinations of these antigens.
Immunoassays that measure titer of host antibody directed against the specific B. anthracis antigens can be used to study the efficacy of experimental anthrax vaccines and the exposure to the bacterium and/or separate antigens.